Web
Analytics
The news is by your side.

CAR-T

US approves first gene therapy for cancer

MIAMI: The United States approved the first gene therapy in the nation on Wednesday -- a treatment that uses a patient's own immune cells to fight leukemia -- opening a new era in the fight against cancer. The treatment is made by Novartis and is called Kymriah, (tisagenlecleucel). This type of immunotherapy, known as a CAR-T cell therapy, was known by CTL019 until now. It was approved by the US Food and Drug Administration for children and young adult patients up to age 25 with a form of acute lymphoblastic leukemia…

Novartis says 82 percent of leukemia patients in remission after CAR-T

BASEL, Switzerland: An experimental cancer therapy being developed by Novartis AG eliminated an aggressive form of blood cancer in 82 percent of children and young adults treated with modified immune cells in a mid-stage trial, the company said on Saturday. Interim results from the multi-center trial for 50 patients with acute lymphoblastic leukemia whose cancer returned or did not respond to other treatment, showed that 41 were disease-free three months after treatment with the drug, called CTL019. The trial results…